LONDON (Reuters) – AstraZeneca said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases.
The academic and commercial tie-ups will allow British-based AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine.
DAVOS, Switzerland (Reuters) – A steep fall in Ebola cases in Liberia will make it hard to prove whether experimental vaccines work in a major clinical trial about to start in the country, the head of the U.S. National Institutes of Health (NIH) said on Saturday.
The NIH might have to move some testing to neighboring Sierra Leone, while regulators could end up approving Ebola shots based on efficacy data from animal tests backed by only limited human evidence, Francis Collins told Reuters.
NIH’s Collins on encouraging inter-disciplinary #science: you can’t herd cats but you can move their food #wef15
DAVOS, Switzerland, Jan 23 (Reuters) – India expects to hold
auctions for private firms to mine and sell coal in the near
future, the country’s coal and power minister Piyush Goyal said
but first wants to deal with mines that are directly linked to
plants that use the fuel.
To boost output and cut imports, Prime Minister Narendra
Modi passed an executive decree in December to open up India’s
nationalised coal industry. Bids have been invited from firms
that use coal for their own power, steel or cement plants.